| First Author | Oya R | Year | 2022 |
| Journal | Int J Mol Sci | Volume | 23 |
| Issue | 3 | PubMed ID | 35163674 |
| Mgi Jnum | J:357600 | Mgi Id | MGI:6876332 |
| Doi | 10.3390/ijms23031747 | Citation | Oya R, et al. (2022) Gene Transfer of Skeletal Muscle-Type Myosin Light Chain Kinase via Adeno-Associated Virus 6 Improves Muscle Functions in an Amyotrophic Lateral Sclerosis Mouse Model. Int J Mol Sci 23(3) |
| abstractText | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that shows progressive muscle weakness. A few treatments exist including symptomatic therapies, which can prolong survival or reduce a symptom; however, no fundamental therapies have been found. As a therapeutic strategy, enhancing muscle force is important for patients' quality of life. In this study, we focused on skeletal muscle-specific myosin regulatory light chain kinase (skMLCK), which potentially enhances muscle contraction, as overexpression of skMLCK was thought to improve muscle function. The adeno-associated virus serotype 6 encoding skMLCK (AAV6/skMLCK) and eGFP (control) was produced and injected intramuscularly into the lower limbs of SOD1(G37R) mice, which are a familial ALS model. AAV6/skMLCK showed the successful expression of skMLCK in the muscle tissues. Although the control did not affect the muscle force in both of the WT and SOD1(G37R) mice, AAV6/skMLCK enhanced the twitch force of SOD1(G37R) mice and the tetanic force of WT and SOD1(G37R) mice. These results indicate that overexpression of skMLCK can enhance the tetanic force of healthy muscle as well as rescue weakened muscle function. In conclusion, the gene transfer of skMLCK has the potential to be a new therapy for ALS as well as for other neuromuscular diseases. |
